|Other Names||Krueppel-like factor 11, Transforming growth factor-beta-inducible early growth response protein 2, TGFB-inducible early growth response protein 2, TIEG-2, KLF11, FKLF, TIEG2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6625a was selected from the N-term region of human TIEG2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Transcription factor. Activates the epsilon- and gamma- globin gene promoters and, to a much lower degree, the beta-globin gene and represses promoters containing SP1-like binding inhibiting cell growth. Represses transcription of SMAD7 which enhances TGF-beta signaling. Induces apoptosis.|
|Tissue Location||Ubiquitous. Higher expression in erythroid cells.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
TIEG2 is a transcription factor. The protein activates the epsilon- and gamma-globin gene promoters and, to a much lower degree, the beta-globin gene and represses promoters containing SP1-like binding inhibiting cell growth. It represses transcription of SMAD7 which enhances TGF-beta signaling. It induces apoptosis.
Kuroda,E., Endocr. J. 56 (2), 275-286 (2009)Ma,L., J. Clin. Endocrinol. Metab. 93 (9), 3644-3649 (2008)
If you have any additional inquiries please email technical services at email@example.com.